Pfizer highlights cancer drugs it thinks could reignite investor interest

AscreenattheNewYorkStockExchangelastNovember.MichaelM.Santiago/GettyImagesPfizerspentmorethanfourhou AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev




leisure time

author：knowledge    Page View：67
Stain of a biopsy specimen of a rhabdoid tumor -- health coverage from STAT
Stain of a biopsy specimen of a rhabdoid tumor. Wikimedia Commons

Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred the cell into murderously rapid growth.

But many tumors don’t have a hyperactive gene. Like the mayhem in “Cat in the Hat,” they are enabled by parental absence. They grow because the genes that are meant to provide discipline, guiding the activity of other genes or self-destructing a cell whose DNA is too damaged, are broken or missing.

advertisement

These tumors have bedeviled researchers for decades. Restoring or fixing a protein is far harder than breaking it. And that’s bad news for humanity: Cancer is far more likely to be caused by such “tumor-suppressor” genes than by one gene run amok. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Why Sanofi got shellacked over its spinoff
Next article： In Memoriam: Notable people who died in 2023